Taylor Barbara S, Wilkin Timothy J, Shalev Noga, Hammer Scott M
University of Texas Health Science Center, San Antonio, TX, USA.
Top Antivir Med. 2013 Apr-May;21(2):75-89.
The 20th Conference on Retroviruses and Opportunistic Infections (CROI) presented important highlights of advances in antiretroviral therapy. Investigators emphasized new approaches to finding a cure for HIV infection, with a special focus on an infant who received combination antiretroviral therapy at 30 hours of age and may have achieved a functional cure in the absence of continued antiretroviral therapy. Challenges and opportunities for sustainable antiretroviral therapy under the Patient Protection and Affordable Care Act (PPACA) were discussed, and investigators around the globe examined attrition through the cascade of care for HIV disease and its implications. Knowledge of barriers to antiretroviral therapy in resource-limited settings (RLSs) continues to expand, as do innovative strategies for improving antiretroviral therapy access and uptake in these settings. Encouraging results from expanded prevention of mother-to-child transmission programs, including option B+, were presented. Prevalence of transmitted (primary) drug resistance appears to be increasing in the United States, and new detection techniques may increase access to resistance testing in RLSs.
第20届逆转录病毒与机会性感染会议(CROI)展示了抗逆转录病毒疗法进展的重要亮点。研究人员强调了寻找治愈HIV感染的新方法,特别关注一名在30小时大时接受联合抗逆转录病毒疗法且在未持续接受抗逆转录病毒治疗的情况下可能实现了功能性治愈的婴儿。讨论了《患者保护与平价医疗法案》(PPACA)下可持续抗逆转录病毒疗法面临的挑战和机遇,全球的研究人员审视了HIV疾病治疗过程中的失访情况及其影响。资源有限地区(RLS)抗逆转录病毒疗法障碍的相关知识不断扩展,改善这些地区抗逆转录病毒疗法可及性和接受度的创新策略亦是如此。会上介绍了扩大预防母婴传播项目(包括B+方案)取得的鼓舞人心的成果。在美国,传播性(原发性)耐药的流行率似乎在上升,新的检测技术可能会增加资源有限地区进行耐药检测的机会。